Expanding the orbit of primary prevention--moving beyond JUPITER.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  New England Journal of Medicine

• Publication date

  2008-11-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMe0808320PMID 18997195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Early stopping of randomized clinical trials for overt efficacy is problematic.

  2008cited by this paper
• A Sustained Mortality Benefit from Screening for Abdominal Aortic Aneurysm

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.

  2006cited by this paper
• Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.

  2005cited by this paper
• Giorgio's paradox.

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

  2003cited by this paper

• Identifying endemic areas and estimating the prevalence of hyperlipidemia in Taiwan's townships.

  2020cites this paper
• Letter from the editor

  2018cites this paper
• Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study

  2017cites this paper
• GeneticLociAssociatedWithC-ReactiveProtein Levels and Risk of Coronary Heart Disease

  2017cites this paper
• Cardiology Meets Personalized Lifestyle Medicine.

  2017cites this paper
• Inflammation as a Therapeutic Target of Betablockers in Ischemic Heart Disease

  2016cites this paper
• Recommandations de prise en charge des dyslipidémies en 2016 en Suisse

  2016cites this paper
• Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

  2015cites this paper
• Critical appraisal training increases understanding and confidence and enhances the use of evidence in diverse categories of learners

  2015cites this paper
• Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective

  2014influential citation
• ACCF/AHA Practice Guideline

  2013cites this paper
• Should we reconsider the routine use of placebo controls in clinical research?

  2012cites this paper
• Biomarkers: hopes and challenges in the path from discovery to clinical practice.

  2012cites this paper
• Prevención de la diabetes de tipo 2. ¿Qué se puede hacer desde la atención primaria? La experiencia del DE-PLAN-CAT

  2012cites this paper
• Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors

  2012cites this paper
• Conflict of interest: will it ever end?

  2012cites this paper
• Meta-analysis of statin effects in women versus men.

  2012cites this paper
• Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management.

  2012cites this paper
• Does Medicalization of Life Imperil Health? Expanding Indications for Diagnosis and Treatment of Chronic “Disease”

  2011cites this paper
• Statins for the primary prevention of cardiovascular disease.

  2011cites this paper
• Risk Prediction in Cardiovascular Medicine Evaluating the Clinical Utility of a Biomarker A Review of Methods for Estimating Health Impact

  2011cites this paper
• The editor's roundtable: JUPITER follow-up.

  2011cites this paper
• Public health impact of statin prescribing strategies based on JUPITER.

  2011cites this paper
• [Statins in primary prophylaxis of cardiovascular diseases].

  2011cites this paper
• Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study

  2011cites this paper
• Statins for the primary prevention of cardiovascular disease (Review)

  2011cites this paper
• Treatment strategies for chronic stable angina

  2011cites this paper
• Foundation/American Heart Association Task Force on Practice Guidelines Asymptomatic Adults : A Report of the American College of Cardiology 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in

  2011cites this paper
• Inflammation as a Marker for the Prediction of Internal Carotid Artery Restenosis Following Eversion Endarterectomy—Evidence From Clinical Studies

  2011cites this paper
• Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction

  2011cites this paper
• The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.

  2011cites this paper
• The Post-JUPITER trial era and the cost of preventive medicine.

  2010cites this paper
• New combination drugs in lipid management

  2010cites this paper
• Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

  2010cites this paper
• [Cardiology news 2009: arterial hypertension, primary and secondary prevention of atherosclerosis, antithrombotic therapy].

  2010cites this paper
• Atherosclerosis I: LDL Cholesterol Lowering

  2010cites this paper
• Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease

  2010cites this paper
• Assessing the c linical Utility of d iagnostics Used in d rug Therapy

  2010cites this paper
• 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2010cites this paper
• in Asymptomatic Adults

  2010cites this paper
• High-Sensitivity C-Reactive Protein: To Measure or not to Measure?~!2009-10-29~!2009-12-22~!2010-04-08~!

  2010cites this paper
• [Rosuvastatin for primary prevention of vascular events : JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin).]

  2010cites this paper
• 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2010cites this paper
• Estatinas en Prevención Primaria

  2010cites this paper
• ACCF/AHA Practice Guideline Practice Guidelines 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults

  2010cites this paper
• The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment

  2010cites this paper
• Is Jupiter also a god of primary prevention?

  2010cites this paper
• Assessing the Clinical Utility of Diagnostics Used in Drug Therapy

  2010cites this paper
• Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?

  2010cites this paper
• After cardiac surgery, how does nutrition fit in with risk factors?

  2010cites this paper
• Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report

  2010cites this paper
• By Jove! What is a clinician to make of JUPITER?

  2010influential citation
• The USPSTF recommendation statement on coronary heart disease risk assessment.

  2010cites this paper
• Weak associations between prognostic biomarkers and disease in preliminary studies illustrates the breach between statistical significance and diagnostic discrimination.

  2010cites this paper
• Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

  2010cites this paper
• JMCP May 2009

  2009cites this paper
• Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

  2009cites this paper
• Use of Obesity Biomarkers in Cardiovascular Epidemiology

  2009cites this paper
• Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness.

  2009cites this paper
• JUPITER: wake up and smell the coffee – The absolute and relative merits of statin use

  2009cites this paper
• C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force

  2009cites this paper
• Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.

  2009cites this paper
• Statins as primary prevention in patients without dislipidaemia

  2009cites this paper
• Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study.

  2009cites this paper
• JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?

  2009cites this paper
• [Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events].

  2009cites this paper
• Electrochemical investigations of the interaction of C-reactive protein (CRP) with a CRP antibody chemically immobilized on a gold surface.

  2009cites this paper
• Fractal Mathematics in Managed Care? How a Simple and Revealing Analysis Could Improve the Forecasting and Management of Medical Costs and Events

  2009cites this paper
• Hyponatremia in patients with central nervous system disorders

  2009cites this paper
• Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.

  2009cites this paper
• JUPITER: A Few Words of Caution

  2009cites this paper
• The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease

  2009influential citation
• JUPITER and the world of stroke medicine.

  2009cites this paper
• Quantitative and qualitative effects of rosuvastatin on LDL‐cholesterol: what is the clinical significance?

  2009cites this paper
• The Jupiter trial: Key findings, controversies, and implications

  2009cites this paper
• Jupiter and accomplish.

  2009cites this paper
• From evidence to practice: consensus in cardiovascular risk assessment and diabetes.

  2009cites this paper
• Prognostische Wertigkeit und klinische Effektivität des hochsensitiven C-reaktiven Proteins als Marker in der Primärprävention der koronaren Herzkrankheit

  2009cites this paper
• Cardiovascular Perspectives JUPITER A Few Words of Caution

  2009cites this paper
• Rosuvastation to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

  2009cites this paper
• Statins Lower Risk of First Cardiovascular Event in Patients with High C-Reactive Protein and Normal LDL Cholesterol RidkerPM,DanielsonE,FonsecaFAH,etal.Rosuvastatintopreventvasculareventsinmenandwomenwithelevated C-reactiveprotein.NEnglJMed2008;359:2195-207.

  2009cites this paper
• El control del colesterol en prevención primaria. ¿Cuanto más bajo, mejor?

  2009cites this paper
• JUPITER: e adesso?

  2009cites this paper
• Studies examine inflammatory biomarker in prevention and prediction of heart disease.

  2009cites this paper
• JUPITER clinical directions--polling results.

  2009cites this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cites this paper
• JUPITER: un nuevo aporte de las estatinas

  2008cites this paper
• The Dawning of the Age of JUPITER

  2008cites this paper
• Tracking of High-Sensitivity C-Reactive Protein after Observation of an Initially Increased Concentration: The JUPITER Study

  2008cites this paper
• More Data on Statins in Primary Prevention — The JUPITER Study

  2008cites this paper
• Practice Guidelines 2010 Accf/aha Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults a Report of the American College of Cardiology Foundation/american Heart Association Task Force on Practice Guidelines ¶ ¶recused from Voting on Section 2.4.2, Recommendations for Measurement of

  year unknowncites this paper
• Title : Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease

  year unknowncites this paper
• Journal of Clinical and Basic Cardiology

  year unknowncites this paper